edoc

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease : a retrospective study of the EBMT Autoimmune Disease Working Party

Daikeler, Thomas and Labopin, Myriam and Di Gioia, Massimo and Abinun, Mario and Alexander, Tobias and Miniati, Irene and Gualandi, Francesca and Fassas, Athanasios and Martin, Thierry and Schwarze, Carl Philipp and Wulffraat, Nico and Buch, Maya and Sampol, Antonia and Carreras, Enric and Dubois, Benedicte and Gruhn, Bernd and Güngör, Tayfun and Pohlreich, David and Schuerwegh, Annemie and Snarski, Emilian and Snowden, John and Veys, Paul and Fasth, Anders and Lenhoff, Stig and Messina, Chiara and Voswinkel, Jan and Badoglio, Manuela and Henes, Jörg and Launay, David and Tyndall, Alan and Gluckman, Eliane and Farge, Dominique and Ebmt Autoimmune Disease Working Party, . (2011) Secondary autoimmune diseases occurring after HSCT for an autoimmune disease : a retrospective study of the EBMT Autoimmune Disease Working Party. Blood, Vol. 118, H. 6. S. 1693-1698.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6005362

Downloads: Statistics Overview

Abstract

To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemophilia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid arthritis (n = 2), sarcoidosis (n = 2), vasculitis (n = 1), psoriasis (n = 1), and psoriatic arthritis (n = 1). After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% ± 2% at 5 years. Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondary AD by multivariate analysis. With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (antiphospholipid syndrome, hemophilia), and 1 death was HSCT-related. This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Rheumatologie FPS (Tyndall)
UniBasel Contributors:De Vere-Tyndall, Alan
Item Type:Article, refereed
Bibsysno:Link to catalogue
Publisher:American Society of Hematology
ISSN:1528-0020
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:27 Mar 2014 13:13
Deposited On:27 Mar 2014 13:13

Repository Staff Only: item control page